Publications by authors named "C Tzanetakos"
Background/objectives: To evaluate the health benefits, costs, and cost-effectiveness of vaccination with bivalent respiratory syncytial virus stabilized prefusion F vaccine (RSVpreF) for the prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV) in Greek adults 60 years of age and older.
Methods: A Markov model was adapted to simulate lifetime risk of health and economic outcomes from the public payer's perspective over a lifetime horizon. Epidemiology, vaccine effectiveness, utilities, and direct medical costs (EUR, 2024) were obtained from published studies, official sources, and local experts.
Article Synopsis
- Ankylosing spondylitis is a chronic inflammatory disease affecting the spine and quality of life, and this study aimed to compare the cost-effectiveness of tofacitinib with existing biologic treatments in Greece for patients not responding to traditional therapies.
- The analysis utilized a decision tree and a Markov model to evaluate treatment effectiveness by measuring patient outcomes like disease activity and functional score improvements while considering treatment costs and potential adverse effects.
- Results indicated that tofacitinib may offer increased quality-adjusted life-years compared to adalimumab in patients who are new to biologic therapies, potentially leading to a more favorable cost-effectiveness profile.
Lorlatinib as a first-line treatment of adult patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: Α cost-effectiveness analysis in Greece.
Expert Rev Pharmacoecon Outcomes Res
March 2024
Objectives: To evaluate the cost-effectiveness of lorlatinib compared to 1 generation anaplastic lymphoma kinase (ALK) TKI crizotinib, and 2 generation TKIs alectinib and brigatinib, for previously untreated patients with ALK+ advanced Non-Small Cell Lung Cancer (aNSCLC).
Methods: A partitioned survival model was locally adapted from a Greek payer perspective over a lifetime horizon. Clinical, safety and utility data were extracted from literature.
Objective: Higher valency pneumococcal conjugate vaccines (PCVs) are expected to improve protection against pneumococcal disease through coverage of additional serotypes. The aim of the present study was to evaluate the cost-effectiveness of 20-valent pneumococcal conjugate vaccine (PCV20) compared to 15-valent pneumococcal conjugate vaccine (PCV15) alone or followed by 23-valent polysaccharide vaccine (PPV23) for adults in Greece.
Methods: A published Markov model was adapted to simulate lifetime risk of clinical and economic outcomes from the public payer's perspective.
Does a Standard Cost-Effectiveness Threshold Exist? The Case of Greece.
Value Health Reg Issues
July 2023
Objectives: This study aimed to systematically review the use of cost-effectiveness (CE) threshold for evaluating pharmacological interventions in Greece.
Methods: A systematic search of PubMed and ScienceDirect was conducted between January 2009 and June 2022. The data of selected studies were extracted using a relevant form and consequently were synthesized.